These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17454609)

  • 1. Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease.
    Carella AM; Biasco S; Nati S; Congiu A; Lerma E
    Leuk Lymphoma; 2007 Mar; 48(3):623-4. PubMed ID: 17454609
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical utility of rituximab in chronic graft-versus-host disease.
    Bates JS; Engemann AM; Hammond JM
    Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease.
    Okamoto M; Okano A; Akamatsu S; Ashihara E; Inaba T; Takenaka H; Katoh N; Kishimoto S; Shimazaki C
    Leukemia; 2006 Jan; 20(1):172-3. PubMed ID: 16239908
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab.
    von Bonin M; Oelschlägel U; Radke J; Stewart M; Ehninger G; Bornhauser M; Platzbecker U
    Transplantation; 2008 Sep; 86(6):875-9. PubMed ID: 18813113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of rituximab in steroid-refractory chronic GVHD.
    Clavert A; Chevallier P; Guillaume T; Delaunay J; Le Gouill S; Mahe B; Dubruille V; Gastinne T; Blin N; Moreau P; Mohty M
    Bone Marrow Transplant; 2013 May; 48(5):734-6. PubMed ID: 23085828
    [No Abstract]   [Full Text] [Related]  

  • 6. Monoclonal antibody therapy for B-cell malignancies.
    Cheson BD
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S2-14. PubMed ID: 16720198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD.
    van Dorp S; Pietersma F; Wölfl M; Verdonck LF; Petersen EJ; Lokhorst HM; Martens E; Theobald M; van Baarle D; Meijer E; Kuball J
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):671-8. PubMed ID: 19450751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NICE announces guidelines for use of rituximab.
    Mayor S
    BMJ; 2003 Oct; 327(7418):766. PubMed ID: 14525854
    [No Abstract]   [Full Text] [Related]  

  • 9. Rituximab for bone lymphoma.
    Savage DG; Staron R
    Ann Intern Med; 2001 Jun; 134(12):1156-7. PubMed ID: 11412072
    [No Abstract]   [Full Text] [Related]  

  • 10. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma.
    Dillman RO
    J Clin Oncol; 2002 Aug; 20(16):3545-57. PubMed ID: 12177115
    [No Abstract]   [Full Text] [Related]  

  • 11. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study.
    Kim SJ; Lee JW; Jung CW; Min CK; Cho B; Shin HJ; Chung JS; Kim H; Lee WS; Joo YD; Yang DH; Kook H; Kang HJ; Ahn HS; Yoon SS; Sohn SK; Min YH; Min WS; Park HS; Won JH
    Haematologica; 2010 Nov; 95(11):1935-42. PubMed ID: 20663943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
    Hao LC; Zhang LZ
    Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
    Ratanatharathorn V; Pavletic S; Uberti JP
    Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for BCL-2-positive cancers.
    Boughton B
    Lancet Oncol; 2003 Feb; 4(2):69. PubMed ID: 12573343
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of rituximab for chemotherapy-resistant multiple tumoral B-LPD in a haemopoietic stem cell recipient.
    Imashuku S; Naya M; Tamura S; An B; Teramura T; Kobayashi M; Nomura K; Taniwaki M
    Br J Haematol; 2002 Jun; 117(3):771-3. PubMed ID: 12028061
    [No Abstract]   [Full Text] [Related]  

  • 16. Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation.
    Puig N; Caballero MD; Alcoceba M; Sebastián E; Balanzategui A; Sarasquete ME; García-Sanz R; González-Díaz M
    Ann Hematol; 2011 Feb; 90(2):227-9. PubMed ID: 20506021
    [No Abstract]   [Full Text] [Related]  

  • 17. Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease: implications for its use?
    Deneberg S; Lerner R; Ljungman P; Ringden O; Hägglund H
    Med Oncol; 2007; 24(3):354-6. PubMed ID: 17873314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid-infusion rituximab in lymphoma treatment.
    Provencio M; Cerdeira S; Bonilla F; Sánchez A; España P
    Ann Oncol; 2006 Jun; 17(6):1027-8. PubMed ID: 16322113
    [No Abstract]   [Full Text] [Related]  

  • 19. [Malignant lymphoma. Current topics. 1. Antibody therapy].
    Izutsu K
    Nihon Naika Gakkai Zasshi; 2008 Jul; 97(7):1620-6. PubMed ID: 18720604
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasmacytoid lymphoma treated with rituximab as first-line monotherapy.
    Blancas I; Zarcos I; Gómez FJ; Delgado MT; Carrillo J; Legerén M; Ríos B; Pacios E; Jurado JM; Sánchez MJ; Fonseca R; García Puche JL
    Clin Transl Oncol; 2009 Oct; 11(10):704-6. PubMed ID: 19828416
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.